Hep C - Anadys Pharmaceuticals Appoints Frank V. Chisari, MD, to Its ...

Anadys Pharmaceuticals Appoints Frank V. Chisari, MD, to Its ...
PharmaLive.com (press release), PA - Jan 10, 2006... robust cell culture model of hepatitis C virus infection, opening the door for the development of antiviral drugs that interrupt all steps in the HCV life cycle ...

Vertex Pharmaceuticals Announces Key Business Objectives for 2006 ...
MSN Money - Jan 9, 2006... "Most notably, in 2005 we presented the first clinical results for our HCV protease inhibitor VX-950, demonstrating unprecedented antiviral activity. ...

Genelabs Regains Compliance With Nasdaq Capital Market Listing ...
Yahoo! News (press release) - Jan 9, 2006... delisting of Genelabs common stock from the Nasdaq Capital Market; fluctuations in Genelabs' stock price; failures or setbacks in our HCV research programs or ...

Intercell's Hepatitis C vaccine meets success criteria for further ...
news aktuell (Pressemitteilung), Germany - Jan 31, 2006... In an IC41 Phase II trial that has already been completed, the strongest T-cell responses were associated with a clinically meaningful decline of HCV-RNA. ...